JP2019511529A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019511529A5 JP2019511529A5 JP2018553368A JP2018553368A JP2019511529A5 JP 2019511529 A5 JP2019511529 A5 JP 2019511529A5 JP 2018553368 A JP2018553368 A JP 2018553368A JP 2018553368 A JP2018553368 A JP 2018553368A JP 2019511529 A5 JP2019511529 A5 JP 2019511529A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- methyl
- oxo
- acceptable salt
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 48
- 206010028980 Neoplasm Diseases 0.000 claims description 22
- 201000011510 cancer Diseases 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 18
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 claims description 17
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 16
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 16
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 16
- 206010033128 Ovarian cancer Diseases 0.000 claims description 15
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 14
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 10
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 10
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 9
- 206010006187 Breast cancer Diseases 0.000 claims description 9
- 208000026310 Breast neoplasm Diseases 0.000 claims description 9
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 9
- 206010009944 Colon cancer Diseases 0.000 claims description 9
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 9
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 9
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 9
- 206010060862 Prostate cancer Diseases 0.000 claims description 9
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 9
- 206010039491 Sarcoma Diseases 0.000 claims description 9
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 9
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 9
- 201000010881 cervical cancer Diseases 0.000 claims description 9
- 201000010536 head and neck cancer Diseases 0.000 claims description 9
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 9
- 201000005202 lung cancer Diseases 0.000 claims description 9
- 208000020816 lung neoplasm Diseases 0.000 claims description 9
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 9
- 201000001441 melanoma Diseases 0.000 claims description 9
- 201000002528 pancreatic cancer Diseases 0.000 claims description 9
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 9
- 201000000849 skin cancer Diseases 0.000 claims description 9
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims description 8
- 208000005017 glioblastoma Diseases 0.000 claims description 8
- 201000007270 liver cancer Diseases 0.000 claims description 7
- 208000014018 liver neoplasm Diseases 0.000 claims description 7
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 6
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 6
- 206010059352 Desmoid tumour Diseases 0.000 claims description 6
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 6
- 201000006827 desmoid tumor Diseases 0.000 claims description 6
- 241000321096 Adenoides Species 0.000 claims description 5
- 201000009030 Carcinoma Diseases 0.000 claims description 5
- 206010011732 Cyst Diseases 0.000 claims description 5
- 210000002534 adenoid Anatomy 0.000 claims description 5
- 208000031513 cyst Diseases 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 208000002517 adenoid cystic carcinoma Diseases 0.000 claims description 4
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims 21
- 239000000047 product Substances 0.000 claims 13
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims 9
- YCBAQKQAINQRFW-UGSOOPFHSA-N 4,4,4-trifluoro-n-[(2s)-1-[[(7s)-5-(2-hydroxyethyl)-6-oxo-7h-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-oxopropan-2-yl]butanamide Chemical compound OCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)CCC(F)(F)F)C)C2=CC=CC=C2C2=CC=CN=C21 YCBAQKQAINQRFW-UGSOOPFHSA-N 0.000 claims 6
- ACCFLVVUVBJNGT-AWEZNQCLSA-N 8-[5-(2-hydroxypropan-2-yl)pyridin-3-yl]-1-[(2s)-2-methoxypropyl]-3-methylimidazo[4,5-c]quinolin-2-one Chemical compound CN1C(=O)N(C[C@H](C)OC)C(C2=C3)=C1C=NC2=CC=C3C1=CN=CC(C(C)(C)O)=C1 ACCFLVVUVBJNGT-AWEZNQCLSA-N 0.000 claims 5
- 239000013066 combination product Substances 0.000 claims 1
- 229940127555 combination product Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 2
- 208000025113 myeloid leukemia Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 208000019838 Blood disease Diseases 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- TXWRERCHRDBNLG-UHFFFAOYSA-N cubane Chemical compound C12C3C4C1C1C4C3C12 TXWRERCHRDBNLG-UHFFFAOYSA-N 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- NSHFLKZNBPJNPA-UHFFFAOYSA-N imidazo[4,5-c]quinolin-2-one Chemical compound C1=CC=C2C3=NC(=O)N=C3C=NC2=C1 NSHFLKZNBPJNPA-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021112585A JP7278331B2 (ja) | 2016-04-12 | 2021-07-07 | がんの処置において使用するための、Ｎｏｔｃｈ阻害剤およびＰＩ３Ｋ／ｍＴＯＲ阻害剤を用いた併用療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662321307P | 2016-04-12 | 2016-04-12 | |
| US62/321,307 | 2016-04-12 | ||
| PCT/US2017/026099 WO2017180385A1 (en) | 2016-04-12 | 2017-04-05 | Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021112585A Division JP7278331B2 (ja) | 2016-04-12 | 2021-07-07 | がんの処置において使用するための、Ｎｏｔｃｈ阻害剤およびＰＩ３Ｋ／ｍＴＯＲ阻害剤を用いた併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019511529A JP2019511529A (ja) | 2019-04-25 |
| JP2019511529A5 true JP2019511529A5 (OSRAM) | 2020-05-14 |
| JP6911048B2 JP6911048B2 (ja) | 2021-07-28 |
Family
ID=58548918
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018553368A Active JP6911048B2 (ja) | 2016-04-12 | 2017-04-05 | がんの処置において使用するための、Ｎｏｔｃｈ阻害剤およびＰＩ３Ｋ／ｍＴＯＲ阻害剤を用いた併用療法 |
| JP2021112585A Active JP7278331B2 (ja) | 2016-04-12 | 2021-07-07 | がんの処置において使用するための、Ｎｏｔｃｈ阻害剤およびＰＩ３Ｋ／ｍＴＯＲ阻害剤を用いた併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021112585A Active JP7278331B2 (ja) | 2016-04-12 | 2021-07-07 | がんの処置において使用するための、Ｎｏｔｃｈ阻害剤およびＰＩ３Ｋ／ｍＴＯＲ阻害剤を用いた併用療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11564929B2 (OSRAM) |
| EP (1) | EP3442528B1 (OSRAM) |
| JP (2) | JP6911048B2 (OSRAM) |
| KR (1) | KR102418766B1 (OSRAM) |
| CN (1) | CN109310685B (OSRAM) |
| AU (1) | AU2017249988C1 (OSRAM) |
| CA (1) | CA3020918A1 (OSRAM) |
| ES (1) | ES2898952T3 (OSRAM) |
| MX (1) | MX380780B (OSRAM) |
| RU (1) | RU2754452C2 (OSRAM) |
| WO (1) | WO2017180385A1 (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI609687B (zh) | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
| ES2881801T3 (es) | 2016-04-12 | 2021-11-30 | Lilly Co Eli | Terapia de combinación con inhibidores de Notch y CDK4/6 para su uso en el tratamiento de cáncer de pulmón |
| WO2017180385A1 (en) | 2016-04-12 | 2017-10-19 | Eli Lilly And Company | Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer |
| CA3025024A1 (en) | 2016-05-20 | 2017-11-23 | Eli Lilly And Company | Combination therapy with notch and pd-1 or pd-l1 inhibitors |
| US11376259B2 (en) | 2016-10-12 | 2022-07-05 | Eli Lilly And Company | Targeted treatment of mature T-cell lymphoma |
| WO2018151836A1 (en) | 2017-02-17 | 2018-08-23 | Fred Hutchinson Cancer Research Center | Combination therapies for treatment of bcma-related cancers and autoimmune disorders |
| WO2019090003A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for b-cell maturation antigen (bcma) |
| SG11202003427XA (en) | 2017-11-06 | 2020-05-28 | Juno Therapeutics Inc | Combination of a cell therapy and a gamma secretase inhibitor |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3812952B2 (ja) | 1996-12-23 | 2006-08-23 | エラン ファーマシューティカルズ，インコーポレイテッド | シクロアルキル、ラクタム、ラクトンおよびその関連化合物およびその医薬組成物、並びに該化合物を用いたβ−アミロイドペプチドの放出および／またはその合成を阻害する方法 |
| AU768269B2 (en) | 1998-10-02 | 2003-12-04 | Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The | Apoptosis inducing agents and methods |
| KR101607288B1 (ko) | 2005-07-01 | 2016-04-05 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| JP4822751B2 (ja) | 2005-07-05 | 2011-11-24 | 富士フイルム株式会社 | 共重合体およびその製造方法 |
| US7706658B2 (en) | 2005-07-05 | 2010-04-27 | Fujifilm Corporation | Copolymer and polymerizable composition |
| US8633179B2 (en) | 2007-03-13 | 2014-01-21 | The Trustees Of Columbia University In The City Of New York | Synergistic interaction of NOTCH-1 inhibitors with glucocorticoids |
| EA017865B1 (ru) | 2007-03-28 | 2013-03-29 | Фармасайкликс, Инк. | Ингибиторы тирозинкиназы брутона |
| US8188069B2 (en) | 2007-08-14 | 2012-05-29 | Eli Lilly And Company | Azepine derivatives as gamma-secretase inhibitors |
| BRPI0906831A2 (pt) | 2008-01-11 | 2019-09-24 | Hoffmann La Roche | uso de um inibidor de gama-secretase para tratamento de câncer |
| JO2885B1 (en) | 2008-12-22 | 2015-03-15 | ايلي ليلي اند كومباني | Protein kinase inhibitors |
| EP2470054B1 (de) * | 2009-08-26 | 2013-12-04 | FrXsh AG | Vorrichtung und verfahren zum mischen von mischgut |
| WO2011060051A1 (en) | 2009-11-12 | 2011-05-19 | University Of Massachusetts | Methods for treating glioblastoma |
| CN102085372A (zh) | 2009-12-04 | 2011-06-08 | 中国医学科学院基础医学研究所 | Notch通路抑制剂用于治疗mTOR活化导致的肿瘤的用途 |
| JP2013532153A (ja) | 2010-06-18 | 2013-08-15 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体 |
| JP5737903B2 (ja) | 2010-10-26 | 2015-06-17 | 三菱重工業株式会社 | 航空機用配管支持構造 |
| JO3003B1 (ar) * | 2011-01-14 | 2016-09-05 | Lilly Co Eli | مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor |
| AR087107A1 (es) * | 2011-07-27 | 2014-02-12 | Lilly Co Eli | Compuesto inhibidor de la señalizacion de la trayectoria notch |
| BR122022000334B1 (pt) | 2011-08-01 | 2023-03-21 | Genentech, Inc | Composição farmacêutica compreendendo um antagonista de ligação ao eixo pd-1 e um inibidor de mek |
| WO2014193898A1 (en) | 2013-05-31 | 2014-12-04 | Merck Sharp & Dohme Corp. | Combination therapies for cancer |
| ES2827679T3 (es) | 2013-08-20 | 2021-05-24 | Merck Sharp & Dohme | Tratamiento del cáncer con una combinación de un antagonista de PD-1 y dinaciclib |
| US10092645B2 (en) | 2014-06-17 | 2018-10-09 | Medimmune Limited | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy |
| KR20170060042A (ko) | 2014-09-13 | 2017-05-31 | 노파르티스 아게 | Alk 억제제의 조합 요법 |
| JP6827415B2 (ja) | 2014-10-31 | 2021-02-10 | メレオ バイオファーマ ５ インコーポレイテッド | 疾患の処置のための併用療法 |
| US20180140602A1 (en) | 2015-04-07 | 2018-05-24 | Novartis Ag | Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives |
| TWI609687B (zh) | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
| CN108025001A (zh) | 2015-07-24 | 2018-05-11 | 安可初克公司 | 用于治疗免疫系统功能障碍的γ分泌酶调节剂 |
| ES2881801T3 (es) | 2016-04-12 | 2021-11-30 | Lilly Co Eli | Terapia de combinación con inhibidores de Notch y CDK4/6 para su uso en el tratamiento de cáncer de pulmón |
| WO2017180385A1 (en) | 2016-04-12 | 2017-10-19 | Eli Lilly And Company | Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer |
| CA3025024A1 (en) | 2016-05-20 | 2017-11-23 | Eli Lilly And Company | Combination therapy with notch and pd-1 or pd-l1 inhibitors |
| KR102512899B1 (ko) | 2016-08-31 | 2023-03-23 | 일라이 릴리 앤드 캄파니 | 고형 종양의 치료를 위한 투약 요법 |
| US11376259B2 (en) | 2016-10-12 | 2022-07-05 | Eli Lilly And Company | Targeted treatment of mature T-cell lymphoma |
| WO2018201056A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| SG11202003427XA (en) | 2017-11-06 | 2020-05-28 | Juno Therapeutics Inc | Combination of a cell therapy and a gamma secretase inhibitor |
-
2017
- 2017-04-05 WO PCT/US2017/026099 patent/WO2017180385A1/en not_active Ceased
- 2017-04-05 RU RU2018138626A patent/RU2754452C2/ru active
- 2017-04-05 ES ES17717989T patent/ES2898952T3/es active Active
- 2017-04-05 JP JP2018553368A patent/JP6911048B2/ja active Active
- 2017-04-05 MX MX2018012456A patent/MX380780B/es unknown
- 2017-04-05 KR KR1020187032282A patent/KR102418766B1/ko active Active
- 2017-04-05 AU AU2017249988A patent/AU2017249988C1/en active Active
- 2017-04-05 US US16/093,117 patent/US11564929B2/en active Active
- 2017-04-05 EP EP17717989.2A patent/EP3442528B1/en active Active
- 2017-04-05 CN CN201780036176.4A patent/CN109310685B/zh active Active
- 2017-04-05 CA CA3020918A patent/CA3020918A1/en active Pending
-
2021
- 2021-07-07 JP JP2021112585A patent/JP7278331B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019511529A5 (OSRAM) | ||
| JP2019511526A5 (OSRAM) | ||
| JP6404242B2 (ja) | がんの治療のための併用療法としてのエリブリンおよびレンバチニブの使用 | |
| JP2014132009A5 (OSRAM) | ||
| TW201210593A (en) | Compositions and methods for treating centrally mediated nausea and vomiting | |
| JP2012500180A5 (OSRAM) | ||
| US8383607B2 (en) | Perifosine and capecitabine as a combined treatment for cancer | |
| JP2014512356A5 (OSRAM) | ||
| RU2010133489A (ru) | Применение ингибиторов гамма-секретазы для лечения рака | |
| JP2013543879A (ja) | 急性骨髄性白血病を治療するための単独またはシタラビンとの組合せにおけるボラセルチブ | |
| JP2014509657A5 (OSRAM) | ||
| KR20190130078A (ko) | 항종양 알칼로이드를 이용한 병용요법 | |
| CA2856646A1 (en) | Combination treatment of cancer | |
| HUE029677T2 (hu) | Készítmények centrálisan mediált émelygés és hányás kezelésére | |
| JP6911048B2 (ja) | がんの処置において使用するための、Ｎｏｔｃｈ阻害剤およびＰＩ３Ｋ／ｍＴＯＲ阻害剤を用いた併用療法 | |
| TWI468161B (zh) | 組合藥劑之醫藥產品、試劑及用途 | |
| CN103491952A (zh) | 用于治疗癌症的新颖联合疗法 | |
| JP2003533485A5 (OSRAM) | ||
| JP2014512355A5 (OSRAM) | ||
| JP2011520846A (ja) | 多発性骨髄腫の治療 | |
| JP2020510075A5 (OSRAM) | ||
| JP2016505050A5 (OSRAM) | ||
| JP2007520522A (ja) | （ａ）ＤＮＡトポイソメラーゼ阻害剤および（ｂ）ＩＡＰ阻害剤の組み合わせ剤 | |
| TW200306185A (en) | Combinations comprising EPOTHILONES and anti-metabolites | |
| JPWO2021206167A5 (OSRAM) |